Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.36 |
| ▸ | HRH1 | P35367 | 5/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636929 | 0.81 | MAOB (0.63) | MAOAMAOBCYP3A4CYP2D6HRH1 | |
| Hydrochloric Acid SCHEMBL2436215 | 0.79 | MAOB (0.61) | MAOAMAOBCYP3A4CYP2D6HRH1 | |
| SCHEMBL27510458 | 0.79 | MAOA (0.59) | MAOAMAOBMAP2K1 | |
| SCHEMBL12015997 | 0.78 | MAOA (0.68) | MAOAMAOBCYP3A4CYP2D6HRH1 | |
| SCHEMBL324588 | 0.78 | MAOA (0.63) | MAOAMAOBKCNH2MAP2K1MAPT | |
| SCHEMBL1638869 | 0.78 | MAOA (0.63) | MAOAMAOBCYP3A4CYP2D6HRH1 | |
| SCHEMBL1639044 | 0.78 | MAOA (0.63) | MAOAMAOBCYP3A4CYP2D6HRH1 | |
| SCHEMBL1681280 | 0.78 | MAOA (0.63) | MAOAMAOBCYP3A4CYP2D6HRH1 | |
| SCHEMBL18897097 | 0.78 | MAOA (0.63) | MAOAMAOBCYP3A4CYP2D6HRH1 | |
| SCHEMBL8206421 | 0.75 | MAOA (0.41) | MAOAMAOBCYP3A4CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404692-B2 | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds | CYCLACEL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYCLACEL LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| WO-2004026848-A1 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPERATION AND THEIR USE AS ANTIMYCOBACTERIAL AGENTS | LUPIN LIMITED (IN) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035870-A1 | Pyrimidin-4-yl-3, 4-Dihydro-2H-Pyrrolo[1,2A] Pyrazin-1-one Compounds | CYP2A13, NR1I3, NR3C2 | MAOA 2047/4885MAOB 1538/4885CYP3A4 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.